Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab.

Margherita RiminiEleonora LoiMario Domenico RizzatoTiziana PressianiCaterina VivaldiEleonora GusmaroliLorenzo AntonuzzoErika MartinelliIngrid GarajovaGuido GiordanoJessica LucchettiMarta SchirripaNoemi CornaraFederico RossariFrancesco VitielloElisabeth AmadeoMara PersanoVittoria Matilde PivaRita BalsanoFrancesca SalaniChiara PircherStefano CascinuMonica NigerLorenzo FornaroLorenza RimassaSara LonardiMario ScartozziPatrizia ZavattariAndrea Casadei-Gardini

Published in: Targeted oncology (2024)

By grouping patients into three clusters with distinct molecular and genomic alterations, our analysis showed that patients included in cluster 2 had higher overall response rates, whereas patients included in cluster 3 had no objective response. Further investigations on larger and external cohorts are needed in order to validate our results.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
gene expression
dna methylation
radiation therapy
genome wide
single molecule